ArticleDiscover oncology2025
Regulation of major histocompatibility complex class-I (MHC-I) gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple negative breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Relevance of USP44 Expression and DNA Methylation Status in Breast Cancer Cell Lines, Tumor Tissues, and Circulating Tumor DNA.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThere are few studies on the effect of DNA methyltransferase (DNMT) inhibitors and immunotherapy on major histocompatibility complex class-I (MHC-I) gene methylation in triple negative breast cancer (TNBC).
methodsThe relationship between the expression of MHC-I and DNA methylation was analyzed using data from The Cancer Genome Atlas (TCGA). The expression of DNMTs and MHC-I, and DNA methylation status of MHC-I genes was analyzed in TNBC cell lines. TNBC cell lines were treated with DNMT inhibitors and programmed cell death-ligand 1 (PD-L1) inhibitor. Then, changes in the expression of DNMT and MHC-I, and methylation patterns of MHC-I genes were analyzed.
resultsTCGA data analysis confirmed that there was an inverse correlation between DNA methylation and expression of MHC-I. After treating TNBC cell lines with DNMT inhibitors and PD-L1 inhibitor alone as well as in combination, the DNA methylation pattern of the HLA-B and HLA-C gene was suppressed, but not the HLA-A gene. After Decitabine treatment, MHC-I expression was increased in BT-20, while after Zebularine treatment, it was increased only in BT-549. MHC-I expression was increased in BT-549 after Atezolizumab treatment, and in MDA-MB231 after co-administration of Decitabine and Atezolizumab.
conclusionsThe effects of DNMT inhibitors and PD-L1 inhibitor were different depending on the TNBC cell lines and the types of drugs, suggesting that the treatment target needs to be applied differently. Further study is needed to determine specific treatment targets and appropriate drugs according to the characteristics of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.